Target intelligence / Profile preview

Neurofascin (NFASC)

Target
NFASC
Molecular classification
Cell adhesion molecule, Immunoglobulin superfamily (L1 subgroup), Ankyrin-binding protein, Membrane protein
01

Overview

Neurofascin (NFASC) is a cell adhesion molecule belonging to the L1 subgroup of the immunoglobulin superfamily, produced in multiple isoforms by alternative splicing, and predominantly expressed in the central and peripheral nervous systems. It is localized at the axon initial segment (AIS) and nodes of Ranvier, where it interacts with voltage-gated sodium channels, ankyrin-G, and βIV-spectrin, forming specialized neuronal domains critical for saltatory conduction and neural signaling. Neurofascin is essential for synapse formation, axonal organization, and myelin-axon integrity, acting as a link between extracellular matrices and the cytoskeleton. Loss or mutation of neurofascin results in severe neurodevelopmental disorders, profound motor deficits, and ataxia; it is also a target of autoantibodies in certain autoimmune neuropathies, increasing disease severity by impairing axonal integrity and repair.

Other names
NeurofascinNFASCKIAA0756NRCAMLFLJ46866NEDCPMDBrain-specific angiogenesis inhibitor 3neurofascin homolog
02

Mechanism of action

Not applicable; monoclonal autoantibodies against neurofascin can be pathogenic by disrupting axonal conduction and myelination

03

Biological functions

Neurite outgrowthNeurite fasciculationAxonal organizationSynapse formationCell adhesionCell migrationMyelinationPropagation of action potentials
04

Disease associations

Neurodevelopmental disorder with central and peripheral motor dysfunctionAutoimmune neurologic disease (e.g., multiple sclerosis, Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy)Congenital hypotonia (severe, with contractures and sensory loss in homozygous mutation)
05

Safety considerations

Potential for severe neurologic autoimmune reactions if targeted by autoantibodiesEssential role in neural development and axonal conduction; therapeutic targeting may risk serious neurological side effects
06

Interacting drugs

none identified in current literature and databases
07

Biomarkers

Presence of anti-neurofascin antibodies (in autoimmune neuropathies such as MS, CIDP, Guillain-Barré syndrome)

Beyond the preview

Go deeper on Neurofascin (NFASC).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neurofascin (NFASC).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call